|
1
|
Li W, Dan G, Jiang J, Zheng Y, Zheng X and
Deng D: Repeated iodine-125 seed implantations combined with
external beam radiotherapy for the treatment of locally recurrent
or metastatic stage III/IV non-small cell lung cancer: A
retrospective study. Radiat Oncol. 11:1192016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
LoCicero JI: General Thoracic
SurgeryShields T, LoCicero JI, Reed C and Feins R: 7th edition.
Lippincott Williams & Wilkins; Philadelphia, PA: pp. 1387–1425.
2009
|
|
3
|
Foucault C, Mordant P, Grand B, Achour K,
Arame A, Dujon A, Le Pimpec Barthes F and Riquet M: Unexpected
extensions of non-small-cell lung cancer diagnosed during surgery:
Revisiting exploratory thoracotomies and incomplete resections.
Interact Cardiovasc Thorac Surg. 16:667–672. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li W, Guan J, Yang L, Zheng X, Yu Y and
Jiang J: Iodine-125 brachytherapy improved overall survival of
patients with inoperable stage III/IV non-small cell lung cancer
versus the conventional radiotherapy. Med Oncol. 32:3952015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tsim S, O'Dowd CA, Milroy R and Davidson
S: Staging of non-small cell lung cancer (NSCLC): a review. Respir
Med. 104:1767–1774. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Johnson M, Colonias A, Parda D, Trombetta
M, Gayou O, Reitz B and Miften M: Dosimetric and technical aspects
of intraoperative I-125 brachytherapy for stage I non-small cell
lung cancer. Phys Med Biol. 52:1237–1245. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dall K, Ford C, Fisher R and Dunning J: Is
there a survival advantage of incomplete resection of
non-small-cell lung cancer that is found to be unresectable at
thoracotomy? Interact Cardiovasc Thorac Surg. 16:529–532. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Aye RW, Mate TP, Anderson HN, Johnson LP
and Hill L: Extending the limits of lung cancer resection. Am J
Surg. 165:572–576. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Heelan RT, Hilaris BS, Anderson LL, Nori
D, Martini N, Watson RC, Caravelli JF and Linares LA: Lung tumors:
Percutaneousimplantation of I-125 sources with CT treatment
planning. Radiology. 164:735–740. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee W, Daly BD, DiPetrillo TA, Morelli DM,
Neuschatz AC, Morr J and Rivard MJ: Limited resection for non-small
cell lung cancer: Observed local control with implantation of I-125
brachytherapy seeds. Ann Thorac Surg. 75:237–243. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Birdas TJ, Koehler RP, Colonias A,
Trombetta M, Maley RH Jr, Landreneau RJ and Keenan RJ: Sublobar
resection with brachytherapy versus lobectomy for stage Ib nonsmall
cell lung cancer. Ann Thorac Surg. 81:434–439. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cahlon O, Zelefsky MJ, Shippy A, Chan H,
Fuks Z, Yamada Y, Hunt M, Greenstein S and Amols H: Ultra-high dose
(86.4 Gy) IMRT for localized prostate cancer: toxicity and
biochemical outcomes. Int J Radiat Oncol Biol Phys. 71:330–337.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zelefsky MJ, Yamada Y, Fuks Z, Zhang Z,
Hunt M, Cahlon O, Park J and Shippy A: Long-term results of
conformal radiotherapy for prostate cancer: Impact of dose
escalation on biochemical tumor control and distant metastases-free
survival outcomes. Int J Radiat Oncol Biol Phys. 71:1028–1033.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Langer M, Kijewski P, Brown R and Ha C:
The effect on minimum tumor dose of restricting target-dose
inhomogeneity in optimized three-dimensional treatment of lung
cancer. Radiother Oncol. 21:245–256. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim TH, Cho KH, Pyo HR, Lee JS, Zo JI, Lee
DH, Lee JM, Kim HY, Hwangbo B, Park SY, et al: Dose-volumetric
parameters for predicting severe radiation pneumo-nitis after
three-dimensional conformal radiation therapy for lung cancer.
Radiology. 235:208–215. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang J, Wang J, Liao A, Zhuang H and Zhao
Y: The direct biologic effects of radioactive 125I seeds on
pancreatic cancer cells PANC-1, at continuous low-dose rates.
Cancer Biother Radiopharm. 24:409–416. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Johnson M, Colonias A, Parda D, Trombetta
M, Gayou O, Reitz B and Miften M: Dosimetric and technical aspects
of intraoperative I-125 brachytherapy for stage I non-small cell
lung cancer. Phys Med Biol. 52:1237–1245. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen H, Bao Y, Yu L, Jia R, Cheng W and
Shao C: Comparison of cellular damage response to low-dose-rate
125I seed irradiation and high-dose-rate gamma irradiation in human
lung cancer cells. Brachytherapy. 11:149–156. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Trombetta MG, Colonias A, Makishi D,
Keenan R, Werts ED, Landreneau R and Parda DS: Tolerance of the
aorta using intraoperative iodine-125 interstitial brachytherapy in
cancer of the lung. Brachytherapy. 7:50–54. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Anglesio S, Calamia E, Fiandra C, Giglioli
FR, Ragona R, Ricardi U and Ropolo R: Prostate brachytherapy with
iodine-125 seeds: Radiation protection issues. Tumori. 91:335–338.
2005.PubMed/NCBI
|
